Dry Age-Related Macular Degeneration (AMD) Companies: Pioneering Treatments for a Leading Cause of Vision Loss

Age-related macular degeneration (AMD) is a leading cause of vision loss in people over the age of 50. It affects the macula, the central part of the retina responsible for sharp, detailed vision. There are two main types of AMD: dry AMD and wet AMD. Dry AMD is the more common form, accounting for about 90% of AMD cases.

The Impact of Dry AMD

Dry AMD is a progressive disease that slowly damages the macula over time. The damage causes vision loss, which can make it difficult to read, drive, and recognize faces. There is no cure for dry AMD, but there are treatments that can help slow the progression of the disease and preserve vision.

Dry AMD Companies: Advancing Treatment Options

Dry Age-Related Macular Degeneration Companies are developing innovative treatments for dry AMD. These treatments aim to address the underlying causes of the disease, such as oxidative stress and inflammation. Some of the leading dry AMD companies include:

• Apellis Pharmaceuticals: Apellis Pharmaceuticals is developing pegpleranib, a first-in-class therapy that targets the complement system, a part of the immune system that plays a role in dry AMD.

• Roche: Roche is developing faricimab, a monoclonal antibody that targets two proteins involved in dry AMD, angiopoietin-2 (ANGPT2) and platelet-derived growth factor (PDGF).

• Novartis: Novartis is developing brolucizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein that plays a role in blood vessel growth in the eye.

• Regeneron: Regeneron is developing CGF114, a protein that targets complement factor H (CFH), a protein that plays a role in the complement system.

• Verucia: Verucia is developing VRD-304, a small molecule that targets the sigma-2 receptor, a protein that plays a role in cell death.

The Future of Dry AMD Treatment

The future of dry AMD treatment is promising, with several potential therapies in development. These therapies have the potential to slow the progression of the disease and preserve vision for people with dry AMD.

In addition to developing new drugs, companies are also exploring other treatment approaches, such as gene therapy and stem cell therapy. These approaches have the potential to be more effective than current treatments and could even cure dry AMD.

With continued research and development, we can hope to see even more effective treatments for dry AMD in the years to come. These treatments could help to prevent vision loss and improve the quality of life for millions of people worldwide.

Additional Notes

• The information in this article is not intended to be a substitute for medical advice. Please consult with your doctor to discuss your individual treatment options.
• The companies mentioned in this article are just a few of the many companies working to develop treatments for dry AMD.
• The field of dry AMD research is rapidly evolving, and new treatments are being developed all the time. Please stay up-to-date on the latest research by visiting the websites of the companies mentioned in this article or by following organizations that focus on AMD research, such as the Age-Related Macular Degeneration Foundation.

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013